產品詳情
簡單介紹：
Anti-SPRN抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-SPRN抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-SPRN
Cat. Number:
Anti-SPRN抗體KL-2149R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are manifested as genetic, infectious or sporadic lethal neurodegenerative disorders involving alterations of the prion protein (PrP). Constitutively expressed Anti-SPRN抗體in normal ***** brain, cellular PrP (PrP(C)) is sensitive to proteinase K digestion and is converted to the disease form, PrPSc, through alterations in protein folding conformation, which make it resistant proteases. SPRN (shadow of prion protein), also known as SHO or SHADOO, is a 151 amino acid cytoplasmic protein that is mainly expressed in brain. SPRN is considered a prion-like protein that has PrP(C)-like neuroprotective activity and may act as a modulator for the biological actions of normal and abnormal PrP. In humans, mutations in the gene encoding SPRN may be associated with variant and sporadic Creutzfeldt-Jakob disease, a degenerative neurological disorder that is incurable and invariably fatal
Also known as:
rCG47959; shadow of prion protein; Anti-SPRN抗體SHO; Protein shadoo; bA108K14.1; C630041J07; FLJ41197; SPRN; Shadow of prion protein precursor; SPRN_MOUSE; SHADOO.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Mouse, Rat, .
●
Immunogen: KLH conjugated synthetic Anti-SPRN抗體peptide derived from mouse Shadow.
●
Predicted Molecular Weight: 12kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-SPRN抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-SPRN抗體
Optimal working dilutions must be determined by the end user.
